Affiliation:
1. Department of Microbiology, Laboratory Group Heidelberg, D-69126 Heidelberg, Germany
Abstract
ABSTRACT
The VITEK 2 (bioMérieux, Marcy L′Ètoile, France) and the Phoenix systems (BD Diagnostic Systems, Sparks, Md.) are automated instruments for rapid organism identification and susceptibility testing. We evaluated the workflow, the time to result, and the performance of identification and susceptibility testing of both instruments. A total of 307 fresh clinical isolates were tested: 141
Enterobacteriaceae
, 22 nonfermenters, 93
Staphylococcus
spp., and 51
Enterococcus
spp. Manipulation time was measured in batches, each with seven isolates, for a total of 39 batches. The mean (± standard deviation [SD]) manipulation time per batch was 20.9 ± 1.8 min for Phoenix and 10.6 ± 1.0 min for VITEK 2 (
P
< 0.001). Mean (±SD) time to result for all bacterial groups was 727 ± 162 min for Phoenix and 506 ± 120 min for VITEK 2 (
P
< 0.001). Concerning identification, Phoenix and VITEK 2 yielded the same results for nonfermenters (100%), staphylococci (97%), and enterococci (100%). For 140
Enterobacteriaceae
strains evaluated, 135 (96%) were correctly identified by Phoenix and 137 (98%) by VITEK 2 (
P
= 0.72). The overall category agreement for all isolates was 97.0% for both instruments. The minor error rate, major error rate, and very major error rate for all bacterial isolates tested were 3.0, 0.3, and 0.6 and 2.8, 0.2, and 1.7 for Phoenix and VITEK 2, respectively (
P
values of 0.76, 0.75, and 0.09). The VITEK 2 system required less manual manipulation time and less time than the Phoenix system to yield results.
Publisher
American Society for Microbiology
Reference17 articles.
1. Abele-Horn, M., S. Suerbaum, and M. Frosch. 2002. Evaluierung des VITEK 2 in der Routinediagnostik. Mikrobiologe12:203-215.
2. Clinical and Financial Benefits of Rapid Bacterial Identification and Antimicrobial Susceptibility Testing
3. Improved Antimicrobial Interventions Have Benefits
4. Center for Devices and Radiological Health 2000. Guidelines on review criteria for assessment of antimicrobial susceptibility devices. U.S. Department of Health and Human Services Food and Drug Administration Washington D.C.
5. Clinical impact of rapid in vitro susceptibility testing and bacterial identification
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献